Ventyx Biosciences, Inc. (VTYX) – Financial Analysis and Stock Price Prediction
Company Overview
- Company Name: Ventyx Biosciences, Inc.
- Ticker Symbol: VTYX
- Industry: Biotechnology
- Sector: Healthcare
- Website: https://ventyxbio.com
- Address: 12790 El Camino Real, Suite 200, San Diego, CA 92130, United States
- Phone: 760 593 4832
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates to address inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. Ventyx Biosciences is also developing other product candidates such as VTX002 for ulcerative colitis, VTX2735 for cryopyrin-associated periodic syndrome, and VTX3232 for CNS disorders.
Financial Analysis
- Market Cap: $412.7 million
- Fiscal Year: 2022
- Full-time Employees: 79
- Revenue: Not available
- Net Income: -$192.96 million
- Profit Margins: Not available
- Trailing EPS: -$3.3
- Forward EPS: -$2.59
- P/E Ratio: Not available
- Payout Ratio: 0%
- Dividend Yield: 0%
- Debt to Equity Ratio: 5.127
Ventyx Biosciences, Inc. has a negative net income and trailing EPS, indicating that the company is currently not profitable. The company's debt to equity ratio is relatively high, suggesting a higher level of debt compared to equity.
Support authors and subscribe to content
This is premium content. Subscribe to read the entire article.
